AstraZeneca and Serum Institute of India’s COVID-19 Vaccine Receive WHO’s EUA to Prevent COVID-19

 AstraZeneca and Serum Institute of India’s COVID-19 Vaccine Receive WHO’s EUA to Prevent COVID-19

AstraZeneca’s Forxiga (dapagliflozin) Receives MHLW’s Approval for the Treatment of Chronic Kidney Disease in Patients with and without T2D

Shots:

  • WHO has granted EUL to AZ’s vaccine for active immunization to prevent COVID-19 in individuals aged ≥18yrs., including those over 65yrs. EUL granted AZ and SII enabling global access to the vaccine
  • The WHO’s SAGE recommended a dosing interval of 8-12wks. and also recommended the use of the vaccine in countries where new variants, including the South African B1.351 variant, are prevalent
  • AZ & SII will work with the COVAX Facility to begin the supply of vaccine across the globe and will be allocated equitably according to the COVAX Allocation Framework

Click here ­to­ read full press release/ article | Ref: AstraZeneca | Image: Mint

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post